Title: Reducing APOE4 in carriers is a therapeutic goal for Alzheimer Disease: Report of the APOE4 National Institute on Aging (NIA) /Alzheimer Disease Sequencing Project (ADSP) Consortium Working Group
Jeffery M Vance, David M Holtzman · 2025
Read Title: Reducing APOE4 in carriers is a therapeutic goal for Alzheimer Disease: Report of the APOE4 National Institute on Aging (NIA) /Alzheimer Disease Sequencing Project (ADSP) Consortium Working Group by Jeffery M Vance, David M Holtzman (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11710726.txt.
Description
Jeffery Vance and David Holtzman report a working group's verdict on the strongest gene risk for Alzheimer's disease, in this 2025 paper. The gene form, APOE4, appears in most late-onset cases and in hundreds of millions of carriers worldwide. The group asked whether therapy should raise or lower its activity.
Experts reviewed human gene data, brain tissue studies, and animal and cell models. The evidence pointed one way: the gene form harms by doing too much, not too little. Lowering its levels in carriers is therefore the right treatment goal, they conclude. The report steers drug programs that target this gene.
Catalog record
| CREATOR | Jeffery M Vance, David M Holtzman |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |